Stem cell sources to treat diabetes

Mark E. Furth, Anthony Atala

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

We review progress towards the goal of utilizing stem cells as a source of engineered pancreatic β-cells for therapy of diabetes. Protocols for the in vitro differentiation of embryonic stem (ES) cells based on normal developmental cues have generated β-like cells that produce high levels of insulin, albeit at low efficiency and without full responsiveness to extracellular levels of glucose. Induced pluripotent stem (iPS) cells also can yield insulin-producing cells following similar approaches. An important recent report shows that when transplanted into mice, human ES-derived cells with a phenotype corresponding to pancreatic endoderm matured to yield cells capable of maintaining near-normal regulation of blood sugar [Kroon et al., 2008]. Major hurdles that must be overcome to enable the broad clinical translation of these advances include teratoma formation by ES and iPS cells, and the need for immunosuppressive drugs. Classes of stem cells that can be expanded extensively in culture but do not form teratomas, such as amniotic fluid-derived stem cells and hepatic stem cells, offer possible alternatives for the production of b-like cells, but further evidence is required to document this potential. Generation of autologous iPS cells should prevent transplant rejection, but may prove prohibitively expensive. Banking strategies to identify small numbers of stem cell lines homozygous for major histocompatibility loci have been proposed to enable beneficial genetic matching that would decrease the need for immunosuppression.

Original languageEnglish
Pages (from-to)507-511
Number of pages5
JournalJournal of Cellular Biochemistry
Volume106
Issue number4
DOIs
StatePublished - Mar 1 2009
Externally publishedYes

Fingerprint

Medical problems
Stem cells
Stem Cells
Induced Pluripotent Stem Cells
Teratoma
Insulin
Endoderm
Histocompatibility
Graft Rejection
Amniotic Fluid
Immunosuppressive Agents
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Immunosuppression
Cues
Blood Glucose
Hepatocytes
Transplants
Efficiency
Phenotype

Keywords

  • Cell transplantation
  • Diabetes
  • Embryonic stem cells
  • Islet of Langerhans

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Stem cell sources to treat diabetes. / Furth, Mark E.; Atala, Anthony.

In: Journal of Cellular Biochemistry, Vol. 106, No. 4, 01.03.2009, p. 507-511.

Research output: Contribution to journalArticle

Furth, Mark E. ; Atala, Anthony. / Stem cell sources to treat diabetes. In: Journal of Cellular Biochemistry. 2009 ; Vol. 106, No. 4. pp. 507-511.
@article{79f67313375c4d60adbef4ecfe9c2908,
title = "Stem cell sources to treat diabetes",
abstract = "We review progress towards the goal of utilizing stem cells as a source of engineered pancreatic β-cells for therapy of diabetes. Protocols for the in vitro differentiation of embryonic stem (ES) cells based on normal developmental cues have generated β-like cells that produce high levels of insulin, albeit at low efficiency and without full responsiveness to extracellular levels of glucose. Induced pluripotent stem (iPS) cells also can yield insulin-producing cells following similar approaches. An important recent report shows that when transplanted into mice, human ES-derived cells with a phenotype corresponding to pancreatic endoderm matured to yield cells capable of maintaining near-normal regulation of blood sugar [Kroon et al., 2008]. Major hurdles that must be overcome to enable the broad clinical translation of these advances include teratoma formation by ES and iPS cells, and the need for immunosuppressive drugs. Classes of stem cells that can be expanded extensively in culture but do not form teratomas, such as amniotic fluid-derived stem cells and hepatic stem cells, offer possible alternatives for the production of b-like cells, but further evidence is required to document this potential. Generation of autologous iPS cells should prevent transplant rejection, but may prove prohibitively expensive. Banking strategies to identify small numbers of stem cell lines homozygous for major histocompatibility loci have been proposed to enable beneficial genetic matching that would decrease the need for immunosuppression.",
keywords = "Cell transplantation, Diabetes, Embryonic stem cells, Islet of Langerhans",
author = "Furth, {Mark E.} and Anthony Atala",
year = "2009",
month = "3",
day = "1",
doi = "10.1002/jcb.22000",
language = "English",
volume = "106",
pages = "507--511",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Stem cell sources to treat diabetes

AU - Furth, Mark E.

AU - Atala, Anthony

PY - 2009/3/1

Y1 - 2009/3/1

N2 - We review progress towards the goal of utilizing stem cells as a source of engineered pancreatic β-cells for therapy of diabetes. Protocols for the in vitro differentiation of embryonic stem (ES) cells based on normal developmental cues have generated β-like cells that produce high levels of insulin, albeit at low efficiency and without full responsiveness to extracellular levels of glucose. Induced pluripotent stem (iPS) cells also can yield insulin-producing cells following similar approaches. An important recent report shows that when transplanted into mice, human ES-derived cells with a phenotype corresponding to pancreatic endoderm matured to yield cells capable of maintaining near-normal regulation of blood sugar [Kroon et al., 2008]. Major hurdles that must be overcome to enable the broad clinical translation of these advances include teratoma formation by ES and iPS cells, and the need for immunosuppressive drugs. Classes of stem cells that can be expanded extensively in culture but do not form teratomas, such as amniotic fluid-derived stem cells and hepatic stem cells, offer possible alternatives for the production of b-like cells, but further evidence is required to document this potential. Generation of autologous iPS cells should prevent transplant rejection, but may prove prohibitively expensive. Banking strategies to identify small numbers of stem cell lines homozygous for major histocompatibility loci have been proposed to enable beneficial genetic matching that would decrease the need for immunosuppression.

AB - We review progress towards the goal of utilizing stem cells as a source of engineered pancreatic β-cells for therapy of diabetes. Protocols for the in vitro differentiation of embryonic stem (ES) cells based on normal developmental cues have generated β-like cells that produce high levels of insulin, albeit at low efficiency and without full responsiveness to extracellular levels of glucose. Induced pluripotent stem (iPS) cells also can yield insulin-producing cells following similar approaches. An important recent report shows that when transplanted into mice, human ES-derived cells with a phenotype corresponding to pancreatic endoderm matured to yield cells capable of maintaining near-normal regulation of blood sugar [Kroon et al., 2008]. Major hurdles that must be overcome to enable the broad clinical translation of these advances include teratoma formation by ES and iPS cells, and the need for immunosuppressive drugs. Classes of stem cells that can be expanded extensively in culture but do not form teratomas, such as amniotic fluid-derived stem cells and hepatic stem cells, offer possible alternatives for the production of b-like cells, but further evidence is required to document this potential. Generation of autologous iPS cells should prevent transplant rejection, but may prove prohibitively expensive. Banking strategies to identify small numbers of stem cell lines homozygous for major histocompatibility loci have been proposed to enable beneficial genetic matching that would decrease the need for immunosuppression.

KW - Cell transplantation

KW - Diabetes

KW - Embryonic stem cells

KW - Islet of Langerhans

UR - http://www.scopus.com/inward/record.url?scp=62649140098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649140098&partnerID=8YFLogxK

U2 - 10.1002/jcb.22000

DO - 10.1002/jcb.22000

M3 - Article

VL - 106

SP - 507

EP - 511

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 4

ER -